Immunovant company information, Employees & Contact Information

Immunovant to Report Q2 Financial Results and Provide Business Update on November 10, 2025 Quiver Quantitative

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 The Manila Times

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 Yahoo Finance

80% of Patients Maintain Normal Thyroid Function: Immunovant's Breakthrough in Graves' Disease Treatment Study Stock Titan

Navigating a new normal with Graves’ disease coppercountrynews.com

Immunovant Announces Promising Six-Month Follow-Up Data for Batoclimab in Uncontrolled Graves’ Disease Patients, Potentially Disease-Modifying Therapy Quiver Quantitative

Immunovant Reports Positive Phase 3 and Phase 2b Results for Batoclimab in Myasthenia Gravis and CIDP NeurologyLive

Immunovant, Inc. to Host Investor Webcast on Phase 3 Study Results of Batoclimab in MG and Phase 2b Study in CIDP Quiver Quantitative

Immunovant Advances IMVT-1402 with 5 IND Clearances Despite Widening Losses Stock Titan

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients Yahoo Finance

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 The Manila Times

Immunovant Announces Leadership Changes with Eric Venker Appointed CEO and Tiago Girao as CFO, Expanding IMVT-1402 Development into New Indications Quiver Quantitative

Immunovant, Inc. Reports Progress on IMVT-1402 Development and Financial Results for Fiscal Q3 2024 Quiver Quantitative

Batoclimab data in Graves’ could signal bigger Immunovant win BioWorld MedTech

Immunovant replaces CEO, makes other changes as Roivant tightens control statnews.com

Previewing Immunovant’s myasthenia gravis study readout — with all its quirky nuance statnews.com

Why Immunovant Stock Blasted Higher Today The Motley Fool

Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role Stock Titan

Immunovant shares surge as early antibody treatment data beats expectations Reuters

How can we change the treatment paradigm in Graves’ disease? statnews.com

Why This Biotech Just Underwent A Surprise C-Suite Sweep Investor's Business Daily

Immunovant won't seek approval for autoimmune drug despite phase 3 win Fierce Biotech

Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another BioSpace

Immunovant Posts 34% R&D Jump in Q1 The Motley Fool

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study (NASDAQ:IMVT) Seeking Alpha

Immunovant Stock: Overvalued Amidst M&A Speculation (NASDAQ:IMVT) Seeking Alpha

Roivant Sciences (ROIV) Announces Positive Results for Batoclimab Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy Studies StreetInsider

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT) Seeking Alpha

Immunovant shunts next-gen FcRn drug ahead of batoclimab in race to rival Vyvgart Fierce Biotech

Immunovant Shifts Focus to Other FcRn Inhibitor, Gives Rival Vyvgart Breathing Room BioSpace

Immunovant Stock: Strategic Edge In The Autoimmune Sector (NASDAQ:IMVT) Seeking Alpha

Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation GlobeNewswire

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease Stock Titan

A patient-focused approach to advancing CIDP treatment statnews.com

IMVT - Immunovant Inc Latest Stock News & Market Updates Stock Titan

Roivant ditches plan to reacquire Immunovant, putting up $200M investment instead Fierce Biotech

Why Shares of Immunovant Are Tanking Today The Motley Fool